

2024 YEAR-END | FACTS+FIGURES

C5Research is a team of experienced and dedicated clinical trial specialists within the Heart, Vascular & Thoracic Institute of Cleveland Clinic. We bring scientific and clinical leadership in cardiovascular disease in combination with operational excellence to conduct Phase I-IV multicenter clinical trials. We understand industry timelines and commit to delivering on time. We bring world class academic leadership to clinical trials and an unbiased viewpoint that satisfies the demanding peer-reviewed scrutiny of the academic and scientific community.

MISSION

Design and conduct innovative clinical research that enhances scientific knowledge and positively impacts the care of patients.

RESEARCH PRIORITIES

Patients Investigators

Integrity Compliance

Functional Teams

Quality Assurance

Contracts & Finance

Information Systems

& Regulatory

- Project & Site Management
- Clinical Endpoints Committee
- Imaging Core Laboratory
- Graphics & Design
- Statistics & Data Management

PHYSICIAN LEADERSHIP

Steven E. Nissen, MD Chief Academic Officer, Heart, Vascular & Thoracic Institute

Venu Menon, MD Associate Director of C5R & Director of Clinical Events Committee

Wael A. Jaber, MD Director, Cardiovascular Imaging Core Laboratory

Rishi Puri, MBBS, PhD Director, Atherosclerosis Imaging Core Laboratory

Vidyasagar Kalahasti, MD Associate Director, Clinical Events Committee

Luke Laffin, MD Co-Director, Center for Blood Pressure Disorders

Milind Desai, MD, MBA Director of Clinical Operations of Cardiovascular Medicine

Erik Van Iterson, PhD, MS Director, Cardiac Rehabilitation & Quality Director, Metabolic Exercise Stress Testing





CLINICAL	TRIAL	RESULTS
----------	-------	---------

Publication of trial results in top tier medical journals having a major impact on the practice of medicine



Tier 1 Medical Journal Publications

Clinical study

participants 2024

CLINICAL TRIALS OVERVIEW



experience, and renowned expertise allows for the dissemination of new knowledge to the clinical community and patient population being studied